Puma Biotechnology Stock Operating Margin
| PBYI Stock | USD 6.42 0.44 6.41% |
As of the 25th of January, Puma Biotechnology holds the Semi Deviation of 4.31, risk adjusted performance of 0.064, and Coefficient Of Variation of 1317.31. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Puma Biotechnology, as well as the relationship between them.
Puma Biotechnology Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.2744 | Revenue |
| Last Reported | Projected for Next Year | ||
| Operating Profit Margin | 0.13 | 0.15 |
Puma | Operating Margin | Build AI portfolio with Puma Stock |
Latest Puma Biotechnology's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Puma Biotechnology over the last few years. It is Puma Biotechnology's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Puma Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.18 % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Puma Operating Margin Regression Statistics
| Arithmetic Mean | 0.52 | |
| Coefficient Of Variation | 2,757 | |
| Mean Deviation | 8.38 | |
| Median | (0.14) | |
| Standard Deviation | 14.31 | |
| Sample Variance | 204.71 | |
| Range | 46.6883 | |
| R-Value | (0.27) | |
| Mean Square Error | 201.97 | |
| R-Squared | 0.08 | |
| Significance | 0.29 | |
| Slope | (0.78) | |
| Total Sum of Squares | 3,275 |
Puma Operating Margin History
Puma Operating Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Puma Biotechnology is extremely important. It helps to project a fair market value of Puma Stock properly, considering its historical fundamentals such as Operating Margin. Since Puma Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Puma Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Puma Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.58) | Earnings Share 0.74 | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Puma Biotechnology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Puma Biotechnology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Puma Biotechnology.
| 10/27/2025 |
| 01/25/2026 |
If you would invest 0.00 in Puma Biotechnology on October 27, 2025 and sell it all today you would earn a total of 0.00 from holding Puma Biotechnology or generate 0.0% return on investment in Puma Biotechnology over 90 days. Puma Biotechnology is related to or competes with Eledon Pharmaceuticals, Abeona Therapeutics, Voyager Therapeutics, Atea Pharmaceuticals, Arcturus Therapeutics, Allogene Therapeutics, and Humacyte. Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to e... More
Puma Biotechnology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Puma Biotechnology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Puma Biotechnology upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.63 | |||
| Information Ratio | 0.0594 | |||
| Maximum Drawdown | 43.28 | |||
| Value At Risk | (5.14) | |||
| Potential Upside | 5.81 |
Puma Biotechnology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Puma Biotechnology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Puma Biotechnology's standard deviation. In reality, there are many statistical measures that can use Puma Biotechnology historical prices to predict the future Puma Biotechnology's volatility.| Risk Adjusted Performance | 0.064 | |||
| Jensen Alpha | 0.3292 | |||
| Total Risk Alpha | (0.09) | |||
| Sortino Ratio | 0.0608 | |||
| Treynor Ratio | 1.15 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Puma Biotechnology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Puma Biotechnology January 25, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.064 | |||
| Market Risk Adjusted Performance | 1.16 | |||
| Mean Deviation | 2.8 | |||
| Semi Deviation | 4.31 | |||
| Downside Deviation | 4.63 | |||
| Coefficient Of Variation | 1317.31 | |||
| Standard Deviation | 4.74 | |||
| Variance | 22.48 | |||
| Information Ratio | 0.0594 | |||
| Jensen Alpha | 0.3292 | |||
| Total Risk Alpha | (0.09) | |||
| Sortino Ratio | 0.0608 | |||
| Treynor Ratio | 1.15 | |||
| Maximum Drawdown | 43.28 | |||
| Value At Risk | (5.14) | |||
| Potential Upside | 5.81 | |||
| Downside Variance | 21.46 | |||
| Semi Variance | 18.56 | |||
| Expected Short fall | (3.15) | |||
| Skewness | 0.1605 | |||
| Kurtosis | 12.1 |
Puma Biotechnology Backtested Returns
Puma Biotechnology appears to be relatively risky, given 3 months investment horizon. Puma Biotechnology maintains Sharpe Ratio (i.e., Efficiency) of 0.0903, which implies the firm had a 0.0903 % return per unit of risk over the last 3 months. We have found thirty technical indicators for Puma Biotechnology, which you can use to evaluate the volatility of the company. Please evaluate Puma Biotechnology's Risk Adjusted Performance of 0.064, semi deviation of 4.31, and Coefficient Of Variation of 1317.31 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Puma Biotechnology holds a performance score of 7. The company holds a Beta of 0.3, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Puma Biotechnology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Puma Biotechnology is expected to be smaller as well. Please check Puma Biotechnology's expected short fall, and the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Puma Biotechnology's historical price patterns will revert.
Auto-correlation | 0.01 |
Virtually no predictability
Puma Biotechnology has virtually no predictability. Overlapping area represents the amount of predictability between Puma Biotechnology time series from 27th of October 2025 to 11th of December 2025 and 11th of December 2025 to 25th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Puma Biotechnology price movement. The serial correlation of 0.01 indicates that just 1.0% of current Puma Biotechnology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.01 | |
| Spearman Rank Test | 0.09 | |
| Residual Average | 0.0 | |
| Price Variance | 0.12 |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Puma Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Puma Biotechnology has an Operating Margin of 0.1757%. This is 100.5% lower than that of the Biotechnology sector and 100.16% lower than that of the Health Care industry. The operating margin for all United States stocks is 103.19% lower than that of the firm.
Puma Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Puma Biotechnology's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Puma Biotechnology could also be used in its relative valuation, which is a method of valuing Puma Biotechnology by comparing valuation metrics of similar companies.Puma Biotechnology is currently under evaluation in operating margin category among its peers.
Puma Biotechnology Current Valuation Drivers
We derive many important indicators used in calculating different scores of Puma Biotechnology from analyzing Puma Biotechnology's financial statements. These drivers represent accounts that assess Puma Biotechnology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Puma Biotechnology's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 123.5M | 189.0M | 204.1M | 148.4M | 170.6M | 162.1M | |
| Enterprise Value | 177.1M | 227.1M | 231.0M | 153.2M | 176.2M | 167.4M |
Puma Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Puma Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Puma Biotechnology's managers, analysts, and investors.Environmental | Governance | Social |
Puma Fundamentals
| Return On Equity | 0.4 | ||||
| Return On Asset | 0.099 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 270.17 M | ||||
| Shares Outstanding | 50.39 M | ||||
| Shares Owned By Insiders | 15.38 % | ||||
| Shares Owned By Institutions | 71.92 % | ||||
| Number Of Shares Shorted | 3.44 M | ||||
| Price To Earning | 18.52 X | ||||
| Price To Book | 2.81 X | ||||
| Price To Sales | 1.53 X | ||||
| Revenue | 230.47 M | ||||
| Gross Profit | 163.04 M | ||||
| EBITDA | 48.08 M | ||||
| Net Income | 30.28 M | ||||
| Cash And Equivalents | 77.96 M | ||||
| Cash Per Share | 1.71 X | ||||
| Total Debt | 74.08 M | ||||
| Debt To Equity | 5.19 % | ||||
| Current Ratio | 2.04 X | ||||
| Book Value Per Share | 2.29 X | ||||
| Cash Flow From Operations | 38.92 M | ||||
| Short Ratio | 8.99 X | ||||
| Earnings Per Share | 0.74 X | ||||
| Price To Earnings To Growth | 0.03 X | ||||
| Target Price | 3.5 | ||||
| Number Of Employees | 172 | ||||
| Beta | 1.18 | ||||
| Market Capitalization | 323.51 M | ||||
| Total Asset | 213.33 M | ||||
| Retained Earnings | (1.31 B) | ||||
| Working Capital | 51.55 M | ||||
| Current Asset | 223.55 M | ||||
| Current Liabilities | 32.44 M | ||||
| Net Asset | 213.33 M |
About Puma Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Puma Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Puma Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Puma Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:Check out Puma Biotechnology Piotroski F Score and Puma Biotechnology Altman Z Score analysis. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.58) | Earnings Share 0.74 | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.